本文已被:浏览 154次 下载 185次
Received:September 25, 2023 Published Online:June 20, 2024
Received:September 25, 2023 Published Online:June 20, 2024
中文摘要: 目的 评价毫火针联合紫蓝方治疗青少年扁平疣的临床疗效和安全性。方法 将2021年3月至2022年3月在无锡市第九人民医院门诊接受诊治的120例青少年扁平疣患者随机分观察组和对照组,每组各60例。观察组应用毫火针联合紫蓝方加减内服、对照组匹多莫德分散片加外用0.1%维A酸乳膏。经6周治疗后,比较患者治疗前后扁平疣皮损严重程度评分、皮肤病生活质量指数(DLQI)评分、治疗有效率、血清白细胞介素-10(IL-10)和干扰素-γ(IFN-γ)水平及不良反应。结果 治疗前,两组患者扁平疣皮损严重程度评分、DLQI评分差异无统计学意义(P>0.05);治疗后,两组患者扁平疣皮损严重程度评分、DLQI评分均较治疗前显著下降(P<0.01),且观察组患者显著低于对照组(P<0.01)。观察组患者总有效率95.00%,显著高于对照组的77.00%,差异有统计学意义(χ2=12.987,P<0.01)。治疗前,两组患者血清IL-10和IFN-γ水平差异均无统计学意义(P > 0.05)。治疗后,观察组患者血清IL-10浓度较治疗前显著降低(P<0.01),并显著低于对照组(P<0.01);观察组患者血清IFN-γ浓度较治疗前显著上升(P<0.01),并显著高于对照组(P<0.01)。治疗过程未出现全身性不良反应。结论 毫火针联合紫蓝方加减用药治疗青少年扁平疣疗效显著、安全性高。
Abstract:Objective To evaluate the clinical efficacy and safety of filiform needles combined with modified Zilan decoction in treating verruca plana in adolescents. Methods A total of 120 adolescents with verruca plana treated at the outpatient clinic of the Wuxi Ninth People's Hospital from March 2021 to March 2022 were randomly assigned to observation group and control group (n=60, each). The observation group received filiform needle treatment combined with oral administration of modified Zilan decoction, while the control group took pidotimod dispersible tablets plus external application of 0.1% tretinoin cream. After six weeks of treatment, the severity scores of verruca plana lesions, Dermatology Life Quality Index (DLQI) scores, treatment efficacy rates, serum levels of interleukin-10 (IL-10) and interferon-γ (IFN-γ), as well as adverse reactions were compared between the two groups before and after treatment. Results Before treatment, there was no significant difference in the severity scores and DLQI scores of verruca plana lesions between the two groups (P>0.05). After treatment, both groups showed a significant decrease in the severity scores and DLQI scores of verruca plana lesions compared to those before treatment (P<0.01), with the observation group significantly lower than the control group (P<0.01). The overall treatment efficacy rate for the observation group was 95.00%, which was significantly higher than the control group's 77.00% (χ2=12.987, P<0.01). Before treatment, there was no significant difference in serum IL-10 and IFN-γ levels between the two groups (P>0.05). After treatment, the serum IL-10 concentration in the observation group was significantly lower than that before treatment (P<0.01) and also significantly lower than that in the control group (P<0.01); the serum IFN-γ concentration in the observation group was significantly higher than that before treatment (P<0.01) and also significantly higher than that in the control group (P<0.01). No systemic adverse reactions occurred during the treatment process. Conclusion Filiform needles combined with modified Zilan decoction have shown significant therapeutic effects and high safety in treating verruca plana in adolescents.
keywords: Verruca plana Human papillomavirus infection Filiform needle Zilan decoction Interleukin-10 Interferon-γ Pidotimod Adolescent
文章编号: 中图分类号:R752.5 R246.7 文献标志码:B
基金项目:江苏省中医药科技发展计划项目(YB201934)
引用文本: